Evaluation of radiation-induced genotoxicity on hu-man melanoma cells (SK-MEL-37) by flow cytometry
DOI:
https://doi.org/10.15392/bjrs.v7i2A.572Keywords:
micronucleus assay, melanoma, radiation, genotoxic damage..Abstract
Micronucleus assay is a test used to evaluate genotoxic damage in cells, which can be caused by various factors, like ionizing radiation. Interactions between radiation energies and DNA can cause breakage, leading to use chromosomal mutations or loss of genetic material, important events that could be induced in solid tumors to mitigate its expansion within human body. Melanoma has been described as a tumor with increased radio resistance. This work evaluated micronuclei percentages (%MN) in human melanoma cells (SK-MEL-37), irradiated by gamma radiation, with doses between 0 and 16Gy. Cell suspensions were irradiated in PBS by a 60Co source in doses between 0 and 16Gy, and incubated by 48h. Then cell membranes were lysed in the presence of SYTOX Green and EMA dyes, preserving nuclear membranes. Using this method, EMA-stained nuclei could be discriminated as those derived from dead cells, and SYTOX nuclei and micronuclei could be quantified. Micronuclei percentages were found to be proportional to dose, (R2 = 0.997). Only the highest dose (16Gy) could induce statistically significant increase of MN (p<0.0001), although cultures irradiated by 4, 8 and 16Gy showed significant increase of dead cell fractions. Calculation of the nuclei-to-beads ratio showed that 8 and 16Gy could reduce melanoma cell proliferation. Results showed that although cell death and loss of proliferative capacity could be observed on cultures irradiated at lower doses, genotoxic damage could be induced only on a higher dose. Resistance to radiation-induced genotoxicity could explain a relatively high radio resistance of melanoma tumors.
Downloads
References
INCA – The National Cancer Institute José Alencar Gomes da Silva. Estimate/2016 – Cancer Incidence in Brazil, Rio de Janeiro, Brazil. 2015. Avaliable at: <http://www.inca.gov.br/estimativa/2016/estimativa-2016-v11.pdf>. Last accessed: 10 May 2017.
MAHADEVAN, A., PATEL, V. L., DAGOGLU, N. Radiation Therapy in the Management of Malignant Melanoma. Oncology (Williston Park), v. 29, p.743–751, 2015.
WHO - World Health Organization. Skin cancers. Avaliable at: <http://www.who.int/uv/faq/skincancer/en/index1.html >. Last accessed: 10 May 2017.
INCA – The National Cancer Institute José Alencar Gomes da Silva. Atlas On-line de Mortalidade. Avaliable at: <https://mortalidade.inca.gov.br/MortalidadeWeb/pages/Modelo01/consultar.xhtml>. Last accessed: 10 May 2017.
National Collaboration Centre for Cancer. Melanoma : assessment and management - NICE guideline NG14: Full guideline. p. 87. 2015. Avaliable at: <http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0079031/pdf/PubMedHealth_PMH0079031.pdf>. Last accessed: 10 May 2017.
SHELLEDY, L.; ROMAN, D. Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma. Journal of the Advanced Practctitioner in Oncology, v. 6, p. 361–5, 2015
Zhu, Z.; Liu, W.; Gotlieb, V. The rapidly evolving therapies for advanced melanoma—Towards immunotherapy, molecular targeted therapy, and beyond. Critical Reviews in Oncology/ Hematology, v. 99, p. 91-99, 2016.
ATKINS, M. Immunotherapy Combinations With Checkpoint Inhibitors in Metastatic Mela-noma: Current Approaches and Future Directions. Seminars in Oncology, v. 42, p. S12-S19, 2015.
FERTIL, B.; MALAISE, E.P. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. International Journal of Radiation Oncology*Biology*Physics, v. 11, p. 1699 – 707, 1985.
SAUSE, W.T.; COOPER, J.S.; RUSH, S.; AGO, C.T.; COSMATOS, D.; COUGHLIN, C.T.; JANJAN, N.; LIPSETT, J. Fraction size in external beam radiation therapy in the treatment of melanoma. International Journal of Radiation Oncology*Biology*Physics. v. 20, p. 429 – 32, 1991.
STEVENS, G.; MCKAY, M.J. Dispelling the myths surrounding radiotherapy for treatment of cutaneous melanoma, The Lancet Oncology, v. 7, p. 575 – 83, 2006.
CHANG, D.T.; AMDUR, R.J.; MORRIS, C.G.; MENDENHALL, W.M. Adjuvant radio-therapy for cutaneous melanoma: Comparing hypofractionation to conventional fractionation. In-ternational Journal of Radiation Oncology*Biology*Physics,v. 66, p.1051–5, 2006.
GUADAGNOLO, B.A.; ZAGARS, G.K. Adjuvant radiation therapy for high-risk nodal metastases from cutaneous melanoma. The Lancet Oncology, v. 10, p. 409-16, 2009.
HENDERSON M.A.; BURMEISTER, B.H.; AINSLIE, J.; FISHER, R.; DI IULIO, J.; SMITHERS, B.M.; HONG, A.; SHANNON, K.; SCOLYER R.A.; CARRUTHERS, S.; COVEN-TRY, B. J.; BABINGTON, S.; DUPRAT, J.; HOEKSTRA, J.; THOMPSON, J. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial, The Lancet Oncology, v. 16, p.1049–60, 2015.
SPEIT, G.; ZELLER, J.; NEUSS, S. The in vivo or ex vivo origin of micronuclei measured in human biomonitoring studies. Mutagenesis, v. 26, p. 107–110, 2011.
HEDDLE, J. A.; FENECH, M.; HAYASHI, M.; MAC GREGOR. Reflections on the development of micronucleus assays. Mutagenesis, v. 26, p. 3–10, 2011.
OCAMPO I.Z.; PASSOS, P.Q.S.; DE CARVALHO, L. R.; DA CRUZ, C.A.L.; ESTEVES-PEDRO, N. M.; DA SILVA, F.M.; HIGA, O. Z.; DIAS, L.A.P.; OKAZAKI, K.; VIEIRA, D. P. In vitro cytotoxic and genotoxic evaluation of peptides used in nuclear medicine (DOTATATE and Ubiquicidin(29-41)) in CHO-K1 cells, Cytotechnology, v. 68, p. 2301-2310, 2016.
BRYCE, S. M.; , BEMIS, J. C.; AVLASEVICH, S.L. DERTINGER SD.In vitro micronucleus assay scored by flow cytometry provides a comprehensive evaluation of cytogenetic damage and cytotoxicity. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, v. 630, p. 78-91, 2007.
Garty, G.; Bigelow, A. W.; REPIN, M.; TURNER, H. C.; BIAN, D.; BALAJEE, A.S.; LYULKO, A. S.; TAVERAS, M.; YAO, Y. L.; BRENNER, D. J. An automated imaging system for radiation biodosimetry. Microscopy Research and Technique, v. 598, p. 587 – 598, 2015.
HALL, E. J.; ASTOR, M.; BEDFORD, J. Basic radiobiology. American journal of clinical oncology, v. 11, p. 220 – 252, 1988.
Published
Issue
Section
License
Copyright (c) 2021 Brazilian Journal of Radiation Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing: The BJRS articles are licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
How to Cite
